A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry

BACKGROUND: Vein graft disease (VGD) impairs graft patency rates and long-term outcomes after coronary artery bypass grafting (CABG). DuraGraft is a novel endothelial-damage inhibitor developed to efficiently protect the structural and functional integrity of the vascular endothelium. The DuraGraft...

Descripción completa

Detalles Bibliográficos
Autores principales: Caliskan, Etem, Sandner, Sigrid, Misfeld, Martin, Aramendi, Jose, Salzberg, Sacha P., Choi, Yeong-Hoon, Satishchandran, Vilas, Iyer, Geeta, Perrault, Louis P., Böning, Andreas, Emmert, Maximilian Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794868/
https://www.ncbi.nlm.nih.gov/pubmed/31615560
http://dx.doi.org/10.1186/s13019-019-1010-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794868/
https://www.ncbi.nlm.nih.gov/pubmed/31615560
http://dx.doi.org/10.1186/s13019-019-1010-z

Ejemplares similares